The comparative risk of hyperkalemia between empagliflozin and dapagliflozin in patients with HF, regardless of ejection fraction phenotype, has been a subject of growing clinical interest, particularly given the widespread use of renin–angiotensin–aldosterone system inhibitors (RAASi), which increase the risk of hyperkalemia. Here, REN is linked to Hyperkalemia.